Cardiovascular Drugs Market Size, Status and Precise Outlook 2020 to 2030 | Merck & Co; Sanofi S.A; Pfizer Inc; Novartis AG

The Cardiovascular Drugs Market Perspective, Comprehensive Analysis along with Major Segments and Forecast, 2020-2030. The Cardiovascular Drugs Market report is a valuable source of data for business strategists. It provides the industry overview with market growth analysis with a historical & futuristic perspective for the following parameters; cost, revenue, demands, and supply data (as applicable). The report explores the current outlook in global and key regions from the perspective of players, countries, product types, and end industries. This Cardiovascular Drugs Market study provides comprehensive data that enhances the understanding, scope, and application of this report.

The global cardiovascular drugs market is expected to decline from $92.5 billion in 2019 to $85.4 billion in 2020 at a compound annual growth rate (CAGR) of -7.8%. The decline is mainly because of the lockdown measures due to the COVID-19 outbreak. The market is then expected to recover and grow at a CAGR of 3% from 2021 and reach $106.1 billion in 2023.

Top Companies:  Merck & Co; Sanofi S.A; Pfizer Inc; Bristol-Myers Squibb Company; Novartis AG

Get a sample copy Of this Report:

https://www.marketinsightsreports.com/reports/06022059398/cardiovascular-drugs-global-market-report-2020-30-covid-19-impact-and-recovery-including-1-by-type-anti-hypertensive-drugs-hypolipidemics-anti-thrombotics-other-drugs-for-cardiovascular-diseases-congestive-heart-failure-anti-arrhythmic-and-anti-anginal-drugs-2-by-distribution-channel-hospital-pharmacies-retail-pharmacies-drug-stores-others-3-by-route-of-administration-oral-parenteral-others-4-by-drug-classification-branded-drugs-generic-drugs-5-by-mode-of-purchase-prescription-based-drugs-over-the-counter-drugs-covering-merck-co-sanofi-s-a-pfizer-inc-bristol-myers-squibb-company-novartis-ag/inquiry?Mode=31&OP

Industry News:

Novartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran

Basel, January 6, 2020: Novartis AG (NYSE: NVS) (“Novartis”) today announced that it has completed the acquisition of The Medicines Company (the “Company”) through the consummation of a merger of its indirect wholly-owned subsidiary, Medusa Merger Corporation (“Purchaser”), with and into the Company, with the Company surviving the merger, without a vote of the Company’s stockholders in accordance with Section 251(h) of the Delaware General Corporation Law. In the merger, each share of the Company’s common stock outstanding immediately prior to the effective time of the merger (other than shares owned by Novartis, Purchaser, the Company, any other subsidiary of Novartis or any subsidiary of the Company, or shares that are held in the Company’s treasury or shares held by any Company stockholder who has properly demanded and perfected appraisal rights under Delaware law) has been converted into the right to receive USD 85.00 per share, net to the seller in cash, without interest and subject to any tax withholding. As a result of the merger, the Company became an indirect wholly-owned subsidiary of Novartis and the Company’s shares have ceased to be traded on the NASDAQ Global Select Market.

U.S. Fda Approves Vyndaqel® And Vyndamax™ For Use In Patients With Transthyretin Amyloid Cardiomyopathy, A Rare And Fatal Disease

NEW YORK , Monday, May 06, 2019 : Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved both VYNDAQEL® (tafamidis meglumine) and VYNDAMAX™ (tafamidis) for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. VYNDAQEL and VYNDAMAX are two oral formulations of the first-in-class transthyretin stabilizer tafamidis, and the first and only medicines approved by the FDA to treat ATTR-CM.

“The approvals of VYNDAQEL and VYNDAMAX are a testament to the significant research and development investment in our innovative cardiovascular outcomes trial, ATTR-ACT. We are proud to bring these medicines to ATTR-CM patients who are in dire need of treatment,” said Brenda Cooperstone, MD, Senior Vice President and Chief Development Officer, Rare Disease, Pfizer Global Product Development. “VYNDAQEL and VYNDAMAX reduce cardiovascular mortality and the frequency of cardiovascular-related hospital stays in patients with wild-type or hereditary forms of this rare disease, giving them a chance for more time with their loved ones.”     

Report Description:

Asia Pacific was the largest region in the global cardiovascular drugs market, accounting for 39% of the market in 2019. North America was the second largest region accounting for 27% of the global cardiovascular drugs market. Africa was the smallest region in the global cardiovascular drugs market.

NOACs are gaining wider acceptance and are replacing traditionally used anti-coagulants such as Warfarin and Heparin. Anti-coagulants have long been used in prevention of thrombus formation in patients suffering with cardiovascular diseases. Use of NOACs makes it easier for patients to continue therapy post discharge as opposed to injections of Heparin and Warfarin which need medical assistance for administration xxviii. Some of the NOACs include Pradaxa (dabigatran etexilate) from Boehringer Ingelheim, Xarelto (rivaroxaban) from Janssen, and Eliquis (apixaban) from Bristol-Myers Squibb.

The cardiovascular drugs market consists of sales of cardiovascular drugs and related services by entities (organizations, sole traders and partnerships) that produce cardiovascular drugs to treat cardiovascular diseases. This industry includes establishments that produce anti-hypertensive drugs to prevent heart failure by controlling blood pressure and hypolipidemic drugs that reduce lipid and lipoprotein levels in the blood. It also consists of establishments which produce antithrombotic drugs to treat arterial and venous thrombosis.

Scope of the Report:

Markets Covered:
1) By Type: Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrhythmic And Anti-Anginal Drugs)

2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies/ Drug Stores; Others

3) By Route Of Administration: Oral; Parenteral; Others

4) By Drug Classification: Branded Drugs; Generic Drugs

5) By Mode Of Purchase: Prescription-Based Drugs; Over-The-Counter Drugs

Metrics Covered: Number of Enterprises; Number of Employees

Countries: Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Colombia; Czech Republic; Denmark; Egypt; Finland; France; Germany; Hong Kong; India; Indonesia; Ireland; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Nigeria; Norway; Peru; Philippines; Poland; Portugal; Romania; Russia; Saudi Arabia; Singapore; South Africa; South Korea; Spain; Sweden; Switzerland; Thailand; Turkey; UAE; UK; USA; Venezuela; Vietnam

Regional Analysis: For a comprehensive understanding of market dynamics, the global Cardiovascular Drugs Market is analyzed across key geographies namely: United States, China, Europe, Japan, Middle East & Africa, India, and others. Each of these regions is analyzed on the basis of market findings across major countries in these regions for a macro-level understanding of the market.

Explore Full Report With Detailed TOC Here:

https://www.marketinsightsreports.com/reports/06022059398/cardiovascular-drugs-global-market-report-2020-30-covid-19-impact-and-recovery-including-1-by-type-anti-hypertensive-drugs-hypolipidemics-anti-thrombotics-other-drugs-for-cardiovascular-diseases-congestive-heart-failure-anti-arrhythmic-and-anti-anginal-drugs-2-by-distribution-channel-hospital-pharmacies-retail-pharmacies-drug-stores-others-3-by-route-of-administration-oral-parenteral-others-4-by-drug-classification-branded-drugs-generic-drugs-5-by-mode-of-purchase-prescription-based-drugs-over-the-counter-drugs-covering-merck-co-sanofi-s-a-pfizer-inc-bristol-myers-squibb-company-novartis-ag?Mode=31&OP

Influence of the Cardiovascular Drugs Market report:
-Comprehensive assessment of all opportunities and risks in the Cardiovascular Drugs Market.
– Cardiovascular Drugs Market recent innovations and major events.
-A detailed study of business strategies for the growth of the Cardiovascular Drugs Market-leading players.
-Conclusive study about the growth plot of the Cardiovascular Drugs market for forthcoming years.
-In-depth understanding of Cardiovascular Drugs Market -particular drivers, constraints, and major micro markets.
-Favorable impression inside vital technological and market latest trends striking the Cardiovascular Drugs Market.  

What are the market factors that are explained in the report?

-Key Strategic Developments: The study also includes the key strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

-Key Market Features: The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments.

–Analytical Tools: The Global Cardiovascular Drugs Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porter’s five forces analysis, feasibility study, and investment return analysis have been used to analyze the growth of the key players operating in the market.

Finally, The Cardiovascular Drugs Market report is the believable source for gaining Market research that will exponentially accelerate your business. The report gives the principle locale, economic situations with the item value, benefit, limit, generation, supply, request, and Market development rate and figure, and so on. This report additionally Present a new task SWOT examination, speculation attainability investigation, and venture return investigation.

Contact Us:

Irfan Tamboli (Head of Sales) – Market Insights Reports
Phone: + 1704 266 3234 | +91-750-707-8687
sales@marketinsightsreports.com|irfan@marketinsightsreports.com

About Us:
MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information, and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

This release was published on openPR.